-------------------------------
                                                 OMB APPROVAL
                                                 -------------------------------
                                                 OMB Number:           3235-0167
                                                 Expires:      November 30, 2010
                                                 Estimated average burden
                                                 hours per response . . .   1.50
                                                 -------------------------------

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     FORM 15

      CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
   12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
   REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

                                     Commission File Number      1-9860
                                                           ---------------------

                           Barr Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                225 Summit Ave, Montvale, New Jersey 07645-1523
--------------------------------------------------------------------------------
  (Address, including zip code, and telephone number, including area code, of
                    registrant's principal executive offices)

                         Common Stock, $0.01 par value
--------------------------------------------------------------------------------
            (Title of each class of securities covered by this Form)

                                      None
--------------------------------------------------------------------------------
       (Titles of all other classes of securities for which a duty to file
                  reports under section 13(a) or 15(d) remains)

     Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:

          Rule 12g-4(a)(1)         [X]
          Rule 12g-4(a)(2)         [ ]
          Rule 12h-3(b)(1)(i)      [X]
          Rule 12h-3(b)(1)(ii)     [ ]
          Rule 15d-6               [ ]

     Approximate number of holders of record as of the certification or notice
date: One
      ---------------





                    Persons who respond to the collection of
                    information contained in this form are not
                    required to respond unless the form displays
SEC2069(02-08)      a currently valid OMB control number.





     Pursuant to the requirements of the Securities Exchange Act of 1934, Barr
Pharmaceuticals, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.

Date: December 23, 2008       By: /s/ Deborah A. Griffin
     --------------------         ----------------------------------------------
                              Name:   Deborah A. Griffin
                              Title:  Vice President and Treasurer